



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-Factor VIII [EL-14] Bulk Size Ab04011-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human scFv format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: EL-14

Alternative Name(s) of Target: AHF; FVIII; Factor 8; anti-hemophilic factor; Coagulation factor VIII; procoagulant component

UniProt Accession Number of Target Protein: P00451

Published Application(s): functional assay, inhibit, IP

Published Species Reactivity: Human

Immunogen: The original antibody was isolated from a human phage display library generated from the peripheral blood of an inhibitor patient and panning the library against factor VIII light chain.

Specificity: This antibody binds the C2 domain of the human factor VIII, a glycoprotein involved in blood coagulation. Factor VIII acts as a cofactor for factor IXa which converts factor X to the activated form Xa in the presence of calcium and phospholipids. Defects in the F8 gene, which encodes Factor VIII, result in the coagulation disorder hemophilia A.

Application Notes: The binding characterization of this antibody towards radiolabeled FVIII light chain and the C2 domain of factor VIII was done using immunoprecipitation. The inhibitory activity of this antibody against factor VIII was determined using a one-stage clotting assay. This antibody was capable of completely eliminating FVIII inhibition by CLB-CAG 117, a C2 domain directed anti-factor VIII antibody (PMID: 10627462). The scFv version of this antibody bound factor VIII light chain with a dissociation constant of $K_d = 1.1$ nM (PMID: 11929772).

Antibody First Published in: van den Brink et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes Blood. 2000 Jan 15;95(2):558-63. PMID:10627462

Note on publication: Describes the generation and epitope mapping of antibodies against C2 domain of factor VIII.

Product Form

Size: 1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.